PSI-14 Effects of maternal nutrient restriction during late gestation on neonatal beef calf serum chemistry and complete blood cell count

2021 ◽  
Vol 99 (Supplement_3) ◽  
pp. 280-280
Author(s):  
Lindsey G Wichman ◽  
Colby A Redifer ◽  
Allison M Meyer

Abstract To determine effects of late gestational nutrient restriction (NR) on neonatal blood chemistry and hematology, primiparous fall-calving crossbred beef heifers [BW: 451 ± 28 (SD) kg; BCS: 5.4 ± 0.7] were individually fed either 100% (control; CON; n = 12) or 70% (n = 13) of NASEM net energy and metabolizable protein requirements for maintenance, pregnancy, and growth from d 160 of gestation to parturition. Calf jugular blood was obtained at 0 (pre-suckling), 6, 12, 24, and 48 h postnatally to determine serum chemistry and complete blood cell count. Data were analyzed with fixed effects of treatment, hour, and their interaction, using repeated measures. Calving date was a fixed effect; calf sex was included when P < 0.25. The treatment x hour interaction (P < 0.10) affected total protein, globulin, gamma-glutamyl transferase (GGT), aspartate aminotransferase (AST), creatinine, creatine kinase, red blood cells (RBC), hemoglobin, hematocrit, sodium, anion gap, and potassium. Total protein and globulin at 6 to 48 h were greater (P ≤ 0.02) in NR calves. Calves from NR heifers had greater (P < 0.08) GGT at 6, 12, and 48 h and greater (P ≤ 0.07) AST at 0 to 24 h. Creatinine at 24 h and creatine kinase at 6 to 24 h were greater (P < 0.04) in NR calves. Hematocrit from 6 to 24 h and RBC and hemoglobin at 6 and 12 h were greater (P ≤ 0.09) in CON calves. Sodium from 0 to 48 h and anion gap at 6 h were greater (P < 0.09) in CON calves. Calves from NR heifers had greater (P = 0.03) 0 h potassium. Treatment affected chloride, which was greater (P = 0.08) in CON calves. These data indicate calves born to nutrient restricted heifers may experience more trauma at calving but have improved passive transfer.

2015 ◽  
Vol 187 ◽  
pp. 60-62 ◽  
Author(s):  
Ana Paula Porto Rödel ◽  
Manuela Borges Sangoi ◽  
Larissa Garcia de Paiva ◽  
Jossana Parcianello ◽  
José Edson Paz da Silva ◽  
...  

2020 ◽  
Vol 28 (1) ◽  
pp. 39-47
Author(s):  
Antonio Pinna ◽  
Tiziana Porcu ◽  
Jacopo Marzano ◽  
Francesco Boscia ◽  
Panagiotis Paliogiannis ◽  
...  

2018 ◽  
Vol 76 (3) ◽  
pp. 344-344
Author(s):  
Aurélie Servonnet ◽  
Hervé Delacour

2011 ◽  
Vol 45 (11) ◽  
pp. 1453-1453 ◽  
Author(s):  
Megan E Musselman ◽  
Linda A Browning ◽  
Dennis Parker ◽  
Suprat Saely

Objective: To describe a case of neuroleptic malignant syndrome (NMS) associated with the use of prochlorperazine in a patient recently hospitalized for NMS secondary to olanzapine. Case Summary: A 28-year-old African American male with a history of schizophrenia was hospitalized 22 days prior to the current admission for an episode of olanzapine-induced NMS. The patient was discharged from our hospital to an outside psychiatric facility. At this facility, the patient developed nausea and was given 2 doses (unknown amount and route) of prochlorperazine. Over the next 24 hours, the patient exhibited signs and symptoms of NMS including fever, agitation, and muscle rigidity. He was transported to the emergency department and became increasingly agitated. Upon admission, the patient was hyperthermic (rectal temperature 39 °C) and tachycardic (heart rate 138 beats/min), with an elevated white blood cell count of 13.5 × 103/μL, creatine kinase 431 units/L, serum sodium 150 mEq/L, blood urea nitrogen 25 mg/dL, and creatinine 1.1 mg/dL A diagnosis of NMS was speculated and infectious causes were excluded. The patient was treated with aggressive fluid resuscitation and rapid cooling measures, as well as bromocriptine and lorazepam. Cooling measures were used for 48 hours, during which time the creatine kinase, white blood cell count, sodium, blood urea nitrogen, and creatinine gradually normalized. The patient was discharged to a psychiatry facility with a treatment regimen of oxcarbazepine 600 mg twice daily, lorazepam 2 mg 3 times daily, and clozapine 25 mg at bedtime, which was titrated over 2 months to 200 mg twice daity. There have been no further occurrences of NMS. Discussion: The patient had all of the major characteristics of NMS with no other likely causative factors that may have contributed to his illness. Use of the Naranjo probability scale suggested that NMS was probably related to prochlorperazine. This case highlights the potential increased risk with the use of prochlorperazine in a patient with a history of olanzapine-induced NMS. Conclusions: NMS should be considered as a rare complication of therapy with antipsychotics and agents that alter dopamine activity, especially in patients with a history of the syndrome. Careful consideration should be given regarding the risks and benefits of using non-antipsychotic dopamine antagonists in patients with a history of antipsychotic-induced NMS.


2020 ◽  
Vol 48 (1) ◽  
pp. 237-237
Author(s):  
Louisa Sethi ◽  
Kathleen Nicol ◽  
Maggie Flowers ◽  
W. Joshua Frazier ◽  
Kevin Kilgallon ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document